... CJ,Conners CK, Potter WZ: Results from 2 proof -of- concept, placebo-controlled studies of atomoxetine in children with attention- deficit/ hyperactivity disorder. J Clin Psychiatry 2002, 63(12):1140-1147.22. ... 11:176http://www.biomedcentral.com/1471-244X/11/176Page 4 of 8 RESEARCH ARTICLE Open AccessComparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attentiondeficithyperactivitydisorder in children and ... Thompson M, Tinline C, et al: Symptom control in children and adolescents with attention- deficit/ hyperactivitydisorder onswitching from immediate-release MPH to OROS MPH Results of a 3-week...
... withAttention -Deficit/ HyperactivityDisorderin theUnited Kingdom. Value Health 2008, 11(3):376-388.28. Brown TE: Emerging Understanding of Attention- Deficit Disorders andComorbidities in Attention- Deficit Disorders ... Modi N, Linde-mulder E, Wigal S: Development of a new once-a-day formula-tion of methylphenidate for the treatment of attention- deficit/ hyperactivity disorder: proof -of- concept and proof -of- product ... ato-moxetine and MPH on the grounds of clinical efficacy in terms of standard measures of ADHD symptom control[21] though there has been increasing evidence in favour of MPH [22]. However, atomoxetine...
... 123–9. THE HISTORY OFATTENTIONDEFICITHYPERACTIVITYDISORDER 9Coinciding with the work of Douglas, researchers in Northern Europe became more interested in the concept ofhyperactivity as a ... criteria for Hyperkinetic Disorder used in the current edition of the International Classifi cation of Diseases (ICD-10) in that specifi c behaviour symptomsof inattention and hyperactivity- impulsivity ... core symptomsof hyperactivity, impulsivity and inatten-tion between boys and girls, together with a preponderance ofsymptomsof inattention over those ofhyperactivity and impulsivity in girls....
... absence of any further increase in treatment inten-sity, a disappointing clinical profile and subsequent lowadoption rate of lisdexamphetamine, and denial of mar-ket access for modafinil and ... CK, Potter WZ: Results from 2 proof -of- concept, pla-cebo-controlled studies of atomoxetine in children with attention- deficit/ hyperactivity disorder. Journal of Clinical Psychi-atry 2002, 63(12):1140-1147.93. ... Skaer TL, Galin RS: National trends in theprevalence of attention- deficit/ hyperactivitydisorder andthe prescribing of methylphenidate among school-age chil-dren: 1990–1995. Clinical Pediatrics...
... adults& apos; requests21 Has trouble concentrating in class22 has difficulty waiting in lines or awaiting turn in games or group situations23 Leaves seat in classroom or other situation in ... of more time spent on video games may also place these individuals at increased riskfor problems in school.BackgroundThe introduction of the telegraph in the nineteenth cen-tury ushered in ... than one hour of time playingvideo games. It would be interesting to examine the lattercohort in more detail to determine if there is a linear rela-tionship between time spent playing video games...
... in the UK for the management of ADHD in school-age children and young people, and are effective in controlling ADHD symptoms [9]. The guidelines produced by the UK National Institute of Clinical ... soon.Clinical use of a modified release methylphenidate in the treatment of childhood attention deficithyperactivity disorder Annals of General Psychiatry 2011, 10:25 doi:10.1186/1744-859X-10-25Inyang ... childhood, affecting over 5% of children worldwide. As well as the core symptomsof inattention, hyperactivity and impulsivity, patients often exhibit learning difficulties and impairment in social...
... and combined t ype, according to the predomi-nant clinical manifestations of inattention, hyperactivity, and impulsivity. The validity of DSM-IV ADHD predo-minantly inattentive and combined types ... 2(CPTimpulsivity)Factor 3(Clinical hyperactivity) Factor 4(Clinicalinattention)SNAP-IVInattention 0.08 0.07 0.36 0.79 Hyperactivity 0.09 0.08 0.85 0.29ADHD-RSInattention 0.19 0.11 -0.06 0.89 Hyperactivity ... 11:65http://www.biomedcentral.com/1471-244X/11/65Page 3 of 10 neurobiological factors of ADHD, especially in the dopa-minergic system [43]. The mechanism of MPH whichinhibitsthereuptakeofdopamineincreasessynapticdopamine and dopaminergic...
... portion of a clini-cal trial design. In a study optimizing the treatment of ADHD in 25 adults, the combination of atomoxetine andmethylphenidate resulted in small statistically significantmean increases ... could need additional dosing of a stimu-lant medication for management ofsymptomsin theevening, but such an increase might lead to insomnia.Thus, the different profiles of the medications can ... placebo having a mean increase in weight of 0.84 kg compared with patients in the ATX/MPH groupwho had a mean decrease in weight of 0.89 kg (P ≤ .05).The mean atomoxetine dose at endpoint was...
... Psychiatr Clin North Am1992, 15:191-222.20. Robison LM, Sclar DA, Skaer TL, Galin RS: National trends in theprevalence of attention- deficit/ hyperactivitydisorder andthe prescribing of methylphenidate ... study endpoint. Improvement in compliance mayreflect increasing capacity to establish a routine of patchadministration with time, although noncompliance isoften underestimated in any clinical ... hours of tutoring, nursing, homehealthcare, or other services increased from 60.2% atbaseline to 77.6% at endpoint. Furthermore, from base-line to endpoint, the percentage of caregivers reporting...
... except of onestudy which included a combined sample of children 6–18 years of age referred for psychiatric services who werediagnosed with a variety of disorders within a spectrum of attention- deficit ... Measuring quality of life in chil-dren with attention- deficit/ hyperactivitydisorder and theirfamilies: Development and evaluation of a new tool. Archives of Pediatric and Adolescent Medicine ... purposes)tive of children in large pediatric populations has severaldistinct benefits beyond the clinical setting. It can aid in identifying subgroups of children who are at-risk forhealth problems, in...
... efficacy in helping smokers with attentiondeficithyperactivitydisorder (ADHD) to stopsmoking.Methods: To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting ... 4 of 6 smoking in adult non-ADHD smokers who were nottrying to stop smoking [5,6]. To date, the only large trial of methylphenidate in smokers has been in smokerswith AttentionDeficitHyperactivity ... of dopamine by binding tothe dopamine transporter in the presynaptic cell mem-brane and increase extracellular dopamine levels [2,3].Similarities in neuropsychologic effects between nicotineand...
... mara.hutz@ufrgs.brADHD, attention- deficit/ hyperactivity disorder; BAIAP2, brain-specific angiogenesis inhibitor 1-associated protein 2 gene; BDKRB2, brady-kinin receptor B2 gene; DAT1, dopamine transporter ... acting specifically in cases of persistent ADHD.BAIAP2 is located at 17q25 and encodes the 53 kDa insulin receptor tyrosine kinase substrate protein (IRSp53), a molecule that participates in ... the signal transduction path-ways of insulin and insulin-like growth factors. This protein is highly expressed in the left cortex and seems to be involved in neuronal proliferation, survival...